Increasing survival motor neuron 2 (SMN2) gene expression may be an effective strategy for the treatment of spinal muscular atrophy. Histone deacetylase inhibitors have been shown to increase SMN transcript and protein levels, but the specific role of histone acetylation in regulating SMN gene expression has not been explored. Using chromatin immunopreciptation, we investigated the levels of acetylated H3 and H4 histones and histone deacetylases (HDACs) associated with different regions of the human and mouse SMN genes in both cultured cells and tissues. We show that the SMN gene has a reproducible pattern of histone acetylation that is largely conserved among different tissues and species. A limited region of the promoter surrounding the transcriptional start site has relatively high levels of histone acetylation, whereas regions further upstream or downstream have lower levels. After histone deacetylase inhibitor treatment, acetylated histone levels increased, particularly at upstream regions, correlating with a two-fold increase in promoter activity. During development in mouse tissues, histone acetylation levels decreased and associated HDAC2 levels increased at the region closest to the transcriptional start site, correlating with a 40-60% decrease in SMN transcript and protein levels. These data indicate that histone acetylation modulates SMN gene expression and that pharmacological manipulation of this epigenetic determinant is feasible. HDAC2, in particular, may be a future therapeutic target for spinal muscular atrophy.
Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by mutation of the survival motor neuron (SMN1) gene (1) . A highly related, centromeric form of the gene, SMN2 , is retained in variable copy number in all SMA patients. Due to a C to T base change in a splice-enhancer region of exon 7, the majority of transcripts from SMN2 lack exon 7 and encode a truncated protein (2, 3) .
Approximately 10-25% of SMN2 transcripts are full-length. SMA is the consequence of reduced levels of functional SMN protein, with clinical severity of disease correlating inversely with SMN2 copy number and SMN protein leve ls (4, 5) .
SMN is a ubiquitously expressed protein with a well-established function in spliceosome assembly (6) . SMN is present in and necessary for the s urvival of all cells that are dependent on RNA splicing, evoking the question of why motor neurons are uniquely sensitive to reduced SMN levels. It has been postulated that SMN may be required for normal motor neuron development. SMN protein is highly expressed in the embryo and fetus, but decreases postnatally in mice and humans (7) (8) (9) (10) . Recently, SMN has been shown to be enriched at the leading edge of neuronal growth cones (11) (12) (13) , and knockdown of SMN in a zebrafish model was found to impair motor axon outgrowth and pathfinding (14).
A promising strategy for treatment of SMA is to increase SMN protein levels, which might be achieved by activating the SMN2 promoter. The human SMN1 and SMN2 gene promoters are nearly identical in sequence and activity (15, 16) . The principal transcriptional initiation site for the SMN genes is located 163 base pairs upstream of the translation initiation site. A second transcriptional initiation site has been at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from mapped to 246 base pairs upstream and appears to be used during fetal development (17) .
Mice have a single Smn gene and its promoter shares sequence homology with the human SMN promoters in an approximately 150 base pair region upstream of the translation initiation site. This region also contains the sequences necessary for minimal promoter activity (17, 18) . Nevertheless, regulatory sequences relevant to SMN expression have been found as far as 4.6 kb upstream of the transcription initiation site in the human genes and 1.2 kb upstream in the mouse gene (15) (16) (17) (18) (19) (20) .
Several studies have demonstrated that compounds which inhibit histone deacetylases (HDACs) activate the human SMN2 promoter (21) , and increase SMN transcript and protein levels in vitro (21-24) . HDACs, acting in opposition to histone acetyltransferases (HATs), control the level of histone acetylation, a post-translational modification of nucleosomal histones that influences gene expression (25, 26) . Histone acetylation promotes gene transcription by relaxing chromatin structure and facilitating access to DNA by the transcriptional machinery, whereas histone deacetylation promotes a condensed chromatin state and transcriptional repression. HDAC inhibitors are now being studied in clinical trials in SMA patients (27) ; however, the mechanism by which they activate SMN2 expression remains unknown. Furthermore, the specific role of histone acetylation in regulating SMN expression has not been explored.
The aim of this study was to investigate the role of histone acetylation in mouse and human SMN gene expression. We show that the SMN gene has a characteristic pattern of histone acetylation that is altered after HDAC inhibitor treatment and during the course of development. These data suggest an important role for histone acetylation in regulating SMN gene expressio n and have important implications for future SMA therapeutics.
Results

The SMN gene has a characteristic pattern of histone acetylation
Chromatin immunoprecipitation (ChIP) assays measure the interaction of protein with DNA in a given chromatin environment within the context of a cell (28, 29). We used ChI P coupled with quantitative PCR to investigate the level of acetylated H3 and H4 histones and RNA polymerase II (Pol II) associated with different segments of the SMN gene ( Fig. 1) .
We first examined the acetylation pattern of the endogenous mouse Smn gene in chromatin isolated from NSC34 cells. This cell line was chosen because it is derived from motor neurons and retains motor neuron characteristics including the ability to generate action potentials and to synthesize, store, and release acetylcholine (30) . For comparison in these cells, we simultaneously examined the mouse ß-globin gene in the region of the translation start site. Histones associated with this gene have been shown to be relatively hypoacetylated in tissues where the gene is transcriptionally silent, but hyperacetylated in erythroid cells where the gene is highly expressed (31) . We found that regions surrounding the Smn transcriptional start site, designated MSP3 and MSP4, had the highest levels of acetylated H3 and H4 histones (Fig. 2) . In contrast, regions approximately 1.3 to 3.5 kb upstream and a region downstream in intron 1 were associated with lower levels of acetylated histones. These low acetylation levels were at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from comparable to the levels seen at the ß-globin gene, a gene which we confirmed to be transcriptionally silent in this cell type (see later results). The regions of Smn with the highest levels of acetylated histones also showed the greatest enrichment of Pol II; Pol II was present at over 2 fold higher levels at MSP3 and at over 5 fold higher levels at MSP4 than at the MSP0-2 or MSP5 Smn regions (Fig. 3) .
We next examined the transgenic human SMN2 gene in these stably transfected NSC34 cells. A similar pattern of histone acetylation was observed with relatively high levels of acetylated histones in the regions surrounding the transcriptional start site, HuSP3 and HuSP4 (Fig. 2) . In contrast, regions HuSP1 and HuSP2, 1.3 to 2.5 kb upstream, had lower acetylated histone levels. Pol II also showed the greatest enrichment in the HuSP3 and HuSP4 regions; approximately 2-3 fold higher than HuSP1 and HuSP2 (Fig. 3) .
In NSC34 cells, the human SMN2 gene is a randomly inserted transgene in a mouse chromatin environment. In order to examine the human SMN2 gene in its native chromatin environment, we analyzed the levels of acetylated histones associated with endogenous human SMN2 gene in chromatin isolated from cells derived from a SMA patient. The 3813 fibroblast cell line, derived from a type I SMA patient, is known to have 2 copies of the SMN2 gene and deletion of the exon 7 and 8 regions in both SMN1 genes (21). A similar pattern of histone acetylation as that observed at the mouse Smn gene and the transgenic human SMN2 gene was present at the endogenous human SMN2 in 3813 cells (Fig. 2) . We also observed this pattern in preparations of chromatin isolated from the 9677 and 2906 fibroblast cell lines (derived from patients with SMA type I and type III with 2 and 4 copies of SMN2 respectively) (data not shown).
HDAC inhibitors activate the SMN2 promoter and modify histone acetylation at the
SMN2 gene
The transcriptional activity of the transgenic human SMN2 promoter was assayed in NSC34 cells that were treated with suberoyl anilide hydroxamic acid (SAHA) at doses ranging from 0 to 1 µM, valproic acid (VPA) at doses ranging from 0 to 5 mM, or valpromide (VPM) at doses ranging from 0 to 5 mM for 24 hours. Promoter activity showed a dose -dependent increase with SAHA and VPA treatment, with a maximum induction of approximately two fold with 1 µM of SAHA treatment and 2.5 mM of VPA treatment (Fig. 4) . Some decrease in promoter activity was seen with higher doses of SAHA (data not shown) and VPA. Valpromide (VPM), a structural analogue of valproic acid lacking HDAC inhibitory activity in vitro (32), did not increase SMN2 promoter activity. We have previously shown that valproic acid also increases SMN transcript and protein levels in fibroblast cell lines derived from SMA patients (21). We have observed similar effects with SAHA treatment in SMA fibroblast cell lines (unpublished observations).
In order to investigate whether HDAC inhibitors might activate SMN2 by directly modifying the histone acetylation pattern at the promoter, we performed ChIP after NSC34 cells had been treated with SAHA (0, 0.5, and 1.0 µM) for 24 hours. After treatment with SAHA, the transgenic human promoter in NSC34 cells showed a two-fold increase in acetylated H3 histones and 2 to 3-fold increase in acetylated H4 histones in upstream regions, HuSP1 and HuSP2 (Fig. 5) , regions of the promoter that were shown to be relatively hypoacetylated at baseline. Downstream regions, HuSP3 and HuSP4, which are relatively hyperacetylated at baseline, showed less marked increases in histone acetylation levels. 
Smn gene expression decreases during development
Previous studies have shown that SMN protein levels decrease with development (7-10) , however it was not known previously whether this was due to transcriptional or post-translational mechanisms. In order to characterize expression patterns of the mouse Western blot confirmed a developmental decrease of SMN protein, as has been previously described. Western blots were performed after quantifying total protein in triplicate in two separate protein quantification assays. In each blot, the density of the SMN band was divided by the density of either the actin or tubulin endogenous controls.
There was variability in actin and tubulin between tissues, making direct comparisons between tissues difficult. In particular, embryonic liver consistently showed lower levels of actin compared to other tissues (Fig. 6B ). Embryonic liver also showed a second, smaller SMN protein species not seen in other tissues. This band was not previously reported in human fetal liver (5) . This may indicate species differences, however it should be noted that different antibodies were used which might also explain this discrepancy. Within each tissue, an approximately 50-85% decrease in the SMN to actin and the SMN to tubulin ratios was observed between embryonic to adult time points in all tissues examined (Fig. 6C) . The decrease in mouse kidney contrasts with the reported lack of developmental down-regulation in human kidney (10) .
Histone acetylation of Smn changes during development
In order to study histone acetylation during the course of development, ChIP was used to assay liver and brain tissues from embryonic and adult time points. Spinal cord was not examined because the mass of embryonic spinal cord tissue that could be obtained at the embryonic time point was insufficient. Overall, the pattern of histone acetylation at the Smn gene in tissues was similar to that observed in cell culture, with relative hyperacetylation in regions surrounding the transcriptional start site, MSP3 and MSP4, and hypoacetylation in upstream regions, MSP0, MSP1, and MSP2, and in intron 1 of the coding region, MSP5. Hyperacetylated regions were 5-12 fold more acetylated than hypoacetylated regions in both liver and brain (Fig. 7) . When comparing embryonic to adult tissues, acetylation of histones H3 and H4 decreased at the MSP4 site; the region closest to the transcriptional start site of the promoter, in both tissues. H3 acetylation decreased by 34% and H4 acetylation decreased by 38% when comparing embryonic to adult liver (Fig. 7) , corresponding to the 66% decrease in SMN transcript (Fig. 6A ). In brain, H3 acetylation decreased by 21% and H4 acetylation decreased by 7% at the MSP4 site, corresponding to a 40% decrease in SMN transcript. Generally, other upstream and downstream regions showed little change in acetylation dur ing development, except MSP3 and MSP5 where we observed an increase in acetylation between embryonic and adult time points, primarily limited to liver. Histone acetylation was also measured at the mouse ß-globin gene in the same samples. As expected, low acetylation levels comparable to those observed in upstream regions of the Smn promoter were seen in both embryonic and adult brain where the ß-globin gene is expressed at neglible levels (see prior results section for ß-globin transcript levels). In liver, a major site of embryonic hematopoesis, there was an 88% decrease in H3 acetylation and a 76% decrease in H4 acetylation between the embryonic and adult time points (Fig. 7) , corresponding to a >99% decrease in ß-globin transcript levels (see prior results section). showed an association with the Smn gene specifically at the MSP4 site, which increased by 55% between the embryonic and adult time points (Fig. 8) . Most striking, however, was the association of HDAC2 with Smn. In embryonic brain, HDAC2 was enriched specifically at the MSP4 site, and the binding levels increased by 311% in adult tissue (Fig. 8) . There was little change in the levels of HDAC1 or HDAC2 binding to other regions of Smn. We also confirmed binding of HDAC1 and HDAC2 to the human SMN2 gene. In preparations of chromatin from 3813 cells that were untreated or treated with VPA, we observed some enrichment of HDAC1 and high levels of enrichment of HDAC2 at the HuSP3 and HuSP4 sites (Fig. 8) .
Discussion
In humans and transgenic mice, SMA disease severity correlates with SMN2 copy number and SMN protein levels. Because expression of eight copies of the SMN2 gene rescues the SMA phenotype evident in mice with reduced SMN levels, it has been These core sequences show the highest promoter activity, while the addition of upstream sequences represses that activity, suggesting the presence of negative regulatory elements upstream. The sequence of the core region is conserved between the mouse and human genes and contains binding sites for the cAMP -response element binding (CREB) and the Sp families of proteins (19, 36) . The CREB family of transcription factors is known to recruit the highly potent histone acetyltransferase, p300/CREB binding protein (CBP) (37) . Recruitment of p300/CBP to SMN could be responsible for the high acetylation levels observed in this region.
Although the overall pattern of SMN histone acetylation is conserved in different species and tissues, we did observe specific changes in acetylation associated with the decrease in mouse Smn gene expression that occurs during development. Using quantitative RT-PCR, we showed that Smn expression decreases by 40-60% between embryonic and adult time points, and using ChIP from liver and brain tissues we showed a decrease in acetylated H3 and H4 levels specifically at the MSP4 site. The decrease in acetylation during development is modest, but small changes in acetylation can be associated with a large change in gene expression. Induction of the mouse ß-globin gene by DMSO, for example, has been shown to produce only a 2-fold increase in ß-globin H3 acetylation with a 150-fold increase in transcript (38) . Neighboring Smn regions, MSP3 and MSP5, showed mild increases in acetylation in liver, but we believe the decrease at MSP4 is the most relevant, as this is the most transcriptionally active region of this gene. HDACs can be divided into three major classes based on sequence homology to yeast HDACs. Class I include HDACs 1, 2, 3, and 8, which are ubiquitously expressed and found almost exclusively in the nucleus; class II include HDACs 4, 5, 7, and 9, which show some tissue specificity and shuttle between the nucleus and cytoplasm; and class III includes the adenine dinucleotide-dependent Sir2 family of HDACs (39, 40) . Using the ChIP methodology, we could detect no association of HDACs 3, 4, or 5 with SMN, but
we were able to demonstrate binding of HDAC1 and HDAC2 to both the human and mouse genes, strongly suggesting that these enzymes may play important roles in regulating the expression of SMN. HDAC1 and 2 are known to be recruited to genes by the Sp1 and Sp3 proteins (40) . Binding of members of the Sp family of proteins to the SMN gene has been implicated in the down-regulation of SMN gene expression that occurs with P19 cell differentiation (19) . It is not surprising that HDAC1 and 2 were found together, as they often coexist in distinct multiprotein complexes that control gene expression, including the Sin3, NuRD, and coREST complexes (40) . HDAC1 and 2 have also been previously implicated in the developmental regulation of genes. They appear to play a role in the tissue-specific changes in gene expression that occur during mammalian epithelial differentiation, for example (41).
HDAC inhibitors have been shown to activate the SMN2 promoter, and here we show that this activation is associated with increases in histone acetylation levels at the SMN2 gene. Surprisingly, the greatest increase in acetylation was not seen in RNA extraction and quantification Tissue was homogenized in 1 ml TRIzol/50-100 mg tissue (Invitrogen), and cells were suspended in 1 ml TRIzol/100 mm plate. RNA was extracted as previously described (21) Protein extraction and western blotting Samples were homogenized in 1 ml of lysis buffer containing 0.1% Nonidet P-40 and 0.5% sodium deoxycholate, and protein was was isolated using phenol chloroform extraction.
Materials and Methods
Cell
Quantitative PCR was used to measure relative amounts of DNA. Sequence specific PCR primer/probe sets were designed to amplify specific regions of the mouse and human SMN genes (Fig 1) . It should be noted that because of the high homology between the human SMN1 and SMN2 genes, our PCR primers do not distinguish between the two genes. If any of the fibroblast cell lines retain an analyzed portion of the SMN1 gene, the ChIP result represents the cumulative enrichment of protein at both the SMN1 and SMN2 genes. This is unlikely in type I SMA patient-derived fibroblast cell lines as deletions in these patients are typically large scale encompassing the entire SMN1 gene (43, 44) . Primers specific for the translational start region of the mouse ß-globin gene 
